Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $59.60 USD
Change Today +0.60 / 1.02%
Volume 549.1K
INSY On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

insys therapeutics inc (INSY) Snapshot

Open
$59.12
Previous Close
$59.00
Day High
$60.88
Day Low
$58.75
52 Week High
04/24/15 - $67.87
52 Week Low
08/1/14 - $22.52
Market Cap
2.1B
Average Volume 10 Days
574.6K
EPS TTM
$1.17
Shares Outstanding
35.7M
EX-Date
--
P/E TM
51.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for INSYS THERAPEUTICS INC (INSY)

Related News

No related news articles were found.

insys therapeutics inc (INSY) Related Businessweek News

No Related Businessweek News Found

insys therapeutics inc (INSY) Details

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients; and Dronabinol SG Capsule, a dronabinol soft gelatin capsule that is generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. Its products candidates also include Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol. The company is headquartered in Chandler, Arizona.

382 Employees
Last Reported Date: 03/3/15

insys therapeutics inc (INSY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $889.2K
Chief Financial Officer
Total Annual Compensation: $383.0K
General Counsel and Corporate Secretary
Total Annual Compensation: $315.5K
Compensation as of Fiscal Year 2014.

insys therapeutics inc (INSY) Key Developments

INSYS Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

INSYS Therapeutics, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, net revenue of the company increased to $70,770,000 versus $41,636,000 a year ago. Income from operations was $11,631,000 against $12,669,000 a year ago. Income before income taxes was $11,756,000 against $12,688,000 a year ago. Net income was $8,023,000 or $0.21 per diluted share compared to $7,658,000 or $0.21 per diluted share per diluted share a year ago. Adjusted income before income taxes was $23,477,000 against $15,143,000 reported last year. Adjusted net income per diluted share was $0.63 against $0.41 a year ago. EBITDA was $12,806,000 against $13,205,000 and adjusted EBITDA was $24,527,000 against $15,660,000 reported last year.

INSYS Therapeutics, Inc. to Report Q1, 2015 Results on May 07, 2015

INSYS Therapeutics, Inc. announced that they will report Q1, 2015 results at 10:00 AM, US Eastern Standard Time on May 07, 2015

INSYS Therapeutics, Inc., Q1 2015 Earnings Call, May 07, 2015

INSYS Therapeutics, Inc., Q1 2015 Earnings Call, May 07, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INSY:US $59.60 USD +0.60

INSY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $8.97 USD +0.05
Array BioPharma Inc $7.73 USD -0.01
Depomed Inc $21.57 USD +0.24
Progenics Pharmaceuticals Inc $5.55 USD -0.04
Spectrum Pharmaceuticals Inc $6.19 USD +0.05
View Industry Companies
 

Industry Analysis

INSY

Industry Average

Valuation INSY Industry Range
Price/Earnings 56.6x
Price/Sales 8.3x
Price/Book 11.4x
Price/Cash Flow 55.0x
TEV/Sales 8.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSYS THERAPEUTICS INC, please visit www.insysrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.